Omalizumab is effective in the long-term control of severe allergic asthma
Authors:
- Jonathan CorrenJCJonathan Corren
- William LumryWLWilliam Lumry
- Jeen LiuJLJeen Liu
- Angel Fowler-TaylorAFAngel Fowler-Taylor
- Niroo GuptaNGNiroo Gupta
- 1 August 2003
- journal article
- clinical trial
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 91 (2) , 154-159
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Anti-Immunoglobulin E Therapy for AsthmaPulmonary Pharmacology & Therapeutics, 2002
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- The diverse potential effector and immunoregulatory roles of mast cells in allergic diseaseJournal of Allergy and Clinical Immunology, 2000
- The role of allergy in the development of asthmaNature, 1999
- Allergic inflammation in upper and lower airwaysAnnals of Allergy, Asthma & Immunology, 1999
- IMMUNOLOGIC BASIS OF ANTIGEN-INDUCED AIRWAY HYPERRESPONSIVENESSAnnual Review of Immunology, 1999
- Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness – a murine modelAllergy, 1999
- Sorting out the cytokines of asthma.Journal of Experimental Medicine, 1996